Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers

Trial Profile

Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2018

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections; Respiratory tract infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Nov 2018 Results (n=21,107) assessing risk of respiratory illness- and RSV-related hospitalizations (RIH and RSVH, respectively) among infants prophylaxed for CDH, standard indications (SI), and those without increased risk (NR), published in the Clinical Infectious Diseases.
    • 04 May 2018 Results (n=23,228) published in the European Journal of Clinical Microbiology and Infectious Diseases.
    • 13 Apr 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top